A Randomised Controlled Trial of Meloxicam, a Cox-2 Inhibitor, to Prevent Hepatocellular Carcinoma Recurrence after Initial Curative Treatment

Trial Profile

A Randomised Controlled Trial of Meloxicam, a Cox-2 Inhibitor, to Prevent Hepatocellular Carcinoma Recurrence after Initial Curative Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2013

At a glance

  • Drugs Meloxicam (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2013 New trial record
    • 27 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top